{"id":"dca7c7e4-77af-4fff-9326-6eb7174d8650","slug":"klow","category":"regeneration","status":"active","sortOrder":1,"imageUrl":"https://peptidesdirect.io/media/pep-shop/images/klow__80mg__obsidian-2026-08.jpg","videoUrl":null,"feedImageUrl":"https://peptidesdirect.io/media/pep-shop/images/klow__packshot__obsidian-2026-08.jpg","publicCode":"2TMR6Z3M","createdAt":"2026-02-27T09:40:41.433Z","updatedAt":"2026-08-18T12:46:56.347Z","translations":[{"id":"d9cedeb5-5497-491c-8ce8-73f8f575429a","productId":"dca7c7e4-77af-4fff-9326-6eb7174d8650","locale":"de","name":"KLOW","description":"\n \n GHK-Cu, BPC-157, TB-500 und KPV, kogefriergetrocknet in einem festen Massenverhältnis von 50:10:10:10, 80 mg insgesamt. Die Mengen je Komponente stehen in der Materialspezifikation unten.\n \n \n Eine 15 Reste umfassende Sequenz, abgeleitet von einem Protein im Magensaft, untersucht in Nagetiermodellen mit Angiogenese, VEGFR2 und dem Akt-eNOS-Signalweg als vorgeschlagenem Mechanismus.\n \n \n Das komplette, 43 Aminosäuren umfassende Peptid (Masse etwa 4963 Da, CAS 77591-33-4), per CoA bestätigt. Es bindet G-Aktin, das Monomer des Aktin-Zytoskeletts.\n \n \n Ein kupfer(II)-bindendes Tripeptid aus humanem Plasma. Fibroblastenkulturstudien maßen Kollagensynthese über picomolare Konzentrationen.\n \n \n Das C-terminale Tripeptid des alpha-Melanozyten-stimulierenden Hormons, untersucht auf NF-kB-Signalgebung und auf PepT1-Aufnahme in Darmmodellen.\n \n \n Es wurde keine Studie identifiziert, die diese vier Peptide in einem Experiment, in irgendeiner Spezies, testet. Das Verhältnis ist eine Formulierungsentscheidung, kein Befund.\n \n\n\n\n Kupferkomplex\n Kollagensynthese\n Aktinbindung\n NF-kB-Signalweg\n Nagetiermodelle\n\n\n## Was ist KLOW\n\nKLOW ist ein Forschungsblend aus vier Peptiden in einer einzigen kogefriergetrockneten Ampulle: GHK-Cu, BPC-157, TB-500 und KPV in einem festen Massenverhältnis von 50:10:10:10, 80 mg insgesamt. Da die vier gemeinsam gefriergetrocknet werden, bevor die Ampulle befüllt wird, liegt das Verhältnis bei der Herstellung fest und kann durch die Rekonstitution nicht geändert werden.\n\nDer Name folgt auf GLOW, den Dreipeptid-Blend aus GHK-Cu, BPC-157 und TB-500, mit KPV, dem C-terminalen Tripeptid von alpha-MSH, als vierter Komponente hinzugefügt. Das ist der gesamte Unterschied zwischen den beiden Produkten: eine Komponente und 10 mg.\n\nWir liefern es als kogefriergetrocknetes Pulver ausschließlich für die Laborforschung. In Lösung nimmt es eine schwache blaue Tönung an, die vom Kupferion in GHK-Cu stammt.\n\n## Wirkweise\n\nVier Komponenten, vier getrennte Literaturen. Keines der folgenden Ergebnisse wurde mit den kombinierten Peptiden erzeugt.\n\n**GHK-Cu** ist ein kupfer(II)-bindendes Tripeptid, identifiziert im humanen Plasma. In kultivierten humanen Hautfibroblasten wurde die Kollagensynthese über picomolare Konzentrationen hinweg gemessen, zusammen mit der Zellzahl (PMID 29986520 fasst die weiteren Genexpressionsdaten zusammen).\n\n**BPC-157** ist eine 15 Aminosäuren umfassende Sequenz, abgeleitet von einem Magensaftprotein. Seine Nagetierliteratur beschreibt VEGFR2- und Akt-eNOS-Signalgebung sowie Angiogenese als vorgeschlagenen Mechanismus (PMID 40789979, PMID 40005999).\n\n**TB-500** ist vollständiges Thymosin beta-4, das wichtigste G-Aktin-bindende Peptid in den meisten Zelltypen. Es bindet monomeres Aktin; die dermale und korneale Modellliteratur maß zytoskelettale Organisation und Zellmigration (PMID 10469335, PMID 23050815).\n\n**KPV** sind die letzten drei Reste von alpha-MSH. Publizierte Arbeit misst NF-kB-Signalwegaktivität und Aufnahme über den intestinalen PepT1-Transporter in Kolitis-Modellen (PMID 18061177, PMID 12750433).\n\nDie ehrliche Zusammenfassung ist kurz: vier getrennt untersuchte Moleküle in einer Ampulle, keine Kombinationsstudie hinter dem Verhältnis, und ein Zertifikat, das den gemessenen Gehalt jeder Komponente angibt statt einer einzelnen kombinierten Zahl.\n\nFür die Rekonstitution ist bakteriostatisches oder steriles Wasser das in publizierten Protokollen übliche Lösungsmittel.\n\n\n\n\n\n## Dokumentation\n\n\n \n \n \n \n \n \n \n\n\n\n\n\n Curr Rev Musculoskelet Med, 2025; Review der Nagetierliteratur und der klinischen Evidenzlücke\n Pharmaceuticals, 2025; Literatur- und Patentreview\n Ann N Y Acad Sci, 2012; Review der dermalen Modellarbeit\n J Invest Dermatol, 1999; grundlegende Studie, Reepithelialisierung und Keratinozyten-Migration\n Int J Mol Sci, 2018; Review auf Basis von Genexpressionsprofilen\n Gastroenterology, 2008; Transporterweg plus Maus-Kolitis-Modelle\n J Pharmacol Exp Ther, 2003; Signalweg-Vergleich in vitro\n\n\n\nDieses Material wird ausschließlich für In-vitro-Forschung und Laborgebrauch verkauft. Nicht bestimmt für den menschlichen oder tierischen Verzehr, medizinische, kosmetische oder Haushaltsanwendungen. Geeignet nur für professionelle Laborumgebungen.\n","shortDescription":"KLOW ist eine kogefriergetrocknete Ampulle mit GHK-Cu, BPC-157, TB-500 und KPV in einem festen Massenverhältnis von 50:10:10:10, 80 mg insgesamt. Jedes Peptid hat seine eigene publizierte Literatur; keine Studie hat alle vier gemeinsam getestet. Gehalt je Komponente auf dem Chargen-CoA.","metaTitle":"KLOW-Blend (GHK-Cu, BPC-157, TB-500, KPV) kaufen | EU","metaDescription":"KLOW: kolyophilisiert GHK-Cu, BPC-157, TB-500 und KPV im festen Massenverhältnis 50:10:10:10. Janoshik-CoA je Komponente, EU-Versand. Nur In-vitro-Forschung."},{"id":"8cd59ef2-340b-4cee-8999-3595e025d2de","productId":"dca7c7e4-77af-4fff-9326-6eb7174d8650","locale":"es","name":"KLOW","description":"\n \n GHK-Cu, BPC-157, TB-500 y KPV, coliofilizados en una proporción fija de masa 50:10:10:10, 80 mg en total. Las cantidades por componente figuran en la especificación del material más abajo.\n \n \n Una secuencia de 15 residuos derivada de una proteína del jugo gástrico, estudiada en modelos de roedores con la angiogénesis, el VEGFR2 y la vía Akt-eNOS como mecanismo propuesto.\n \n \n El péptido completo de 43 aminoácidos (masa de unos 4963 Da, CAS 77591-33-4), confirmado por CoA. Se une a la G-actina, el monómero del citoesqueleto de actina.\n \n \n Un tripéptido que une cobre(II), presente en el plasma humano. Los estudios en cultivo de fibroblastos midieron la síntesis de colágeno en concentraciones picomolares.\n \n \n El tripéptido C-terminal de la hormona alfa estimulante de los melanocitos, estudiado por la señalización de NF-kB y por la captación mediante PepT1 en modelos intestinales.\n \n \n No se identificó ningún estudio que probara estos cuatro péptidos en un mismo experimento, en ninguna especie. La proporción es una decisión de formulación, no un hallazgo.\n \n\n\n\n Complejo de cobre\n Síntesis de colágeno\n Unión a actina\n Vía NF-kB\n Modelos en roedores\n\n\n## Qué es KLOW\n\nKLOW es una mezcla de investigación de cuatro péptidos en un único vial coliofilizado: GHK-Cu, BPC-157, TB-500 y KPV en una proporción fija de masa 50:10:10:10, 80 mg en total. Como los cuatro se liofilizan juntos antes de llenar el vial, la proporción queda fijada en la fabricación y no puede cambiarse mediante la reconstitución.\n\nEl nombre sigue al de GLOW, la mezcla de tres péptidos formada por GHK-Cu, BPC-157 y TB-500, con el KPV, el tripéptido C-terminal de la alfa-MSH, añadido como cuarto componente. Esa es toda la diferencia entre los dos productos: un componente y 10 mg.\n\nLo suministramos como polvo coliofilizado, solo para investigación de laboratorio. En solución adquiere un tono azulado tenue, que proviene del ion de cobre del GHK-Cu.\n\n## Cómo funciona\n\nCuatro componentes, cuatro bibliografías separadas. Ninguno de los resultados siguientes se generó con los péptidos combinados.\n\n**El GHK-Cu** es un tripéptido que une cobre(II), identificado en el plasma humano. En fibroblastos cutáneos humanos cultivados, la síntesis de colágeno se midió en concentraciones picomolares junto con el número de células (el PMID 29986520 revisa los datos más amplios de expresión génica).\n\n**El BPC-157** es una secuencia de 15 aminoácidos derivada de una proteína del jugo gástrico. Su bibliografía en roedores describe la señalización por VEGFR2 y Akt-eNOS y la angiogénesis como mecanismo propuesto (PMID 40789979, PMID 40005999).\n\n**El TB-500** es la timosina beta-4 de longitud completa, el principal péptido de unión a G-actina en la mayoría de los tipos celulares. Se une a la actina monomérica; la bibliografía de modelos dérmicos y corneales midió la organización del citoesqueleto y la migración celular (PMID 10469335, PMID 23050815).\n\n**El KPV** son los tres últimos residuos de la alfa-MSH. El trabajo publicado mide la actividad de la vía NF-kB y la captación a través del transportador intestinal PepT1 en modelos de colitis (PMID 18061177, PMID 12750433).\n\nEl resumen honesto es breve: cuatro moléculas estudiadas por separado en un solo vial, ningún estudio de combinación detrás de la proporción, y un certificado que informa del contenido medido de cada componente en lugar de una única cifra combinada.\n\nPara la reconstitución, el disolvente habitual en los protocolos publicados es agua bacteriostática o estéril.\n\n\n\n\n\n## Documentación\n\n\n \n \n \n \n \n \n \n\n\n\n\n\n Curr Rev Musculoskelet Med, 2025; revisión de la bibliografía en roedores y la brecha de evidencia clínica\n Pharmaceuticals, 2025; revisión de bibliografía y patentes\n Ann N Y Acad Sci, 2012; revisión del trabajo en modelos dérmicos\n J Invest Dermatol, 1999; estudio fundacional, reepitelización y migración de queratinocitos\n Int J Mol Sci, 2018; revisión basada en perfiles de expresión génica\n Gastroenterology, 2008; vía del transportador más modelos de colitis en ratones\n J Pharmacol Exp Ther, 2003; comparación de vías in vitro\n\n\n\nEste material se vende exclusivamente para uso en investigación in vitro y de laboratorio. No está destinado al consumo humano ni animal, ni a aplicaciones médicas, cosméticas o domésticas. Apto únicamente para entornos de laboratorio profesionales.\n","shortDescription":"KLOW es un vial coliofilizado con GHK-Cu, BPC-157, TB-500 y KPV en una proporción fija de masa 50:10:10:10, 80 mg en total. Cada péptido cuenta con su propia bibliografía publicada; ningún estudio ha probado los cuatro juntos. Contenido por componente en el CoA del lote.","metaTitle":"Comprar Mezcla KLOW (GHK-Cu, BPC-157, TB-500, KPV) | UE","metaDescription":"KLOW: GHK-Cu, BPC-157, TB-500 y KPV coliofilizados en proporción másica fija 50:10:10:10. CoA Janoshik por componente, envío UE. Solo investigación in vitro."},{"id":"fe7fe9df-66c7-42d6-8782-d47c76af8dfe","productId":"dca7c7e4-77af-4fff-9326-6eb7174d8650","locale":"da","name":"KLOW","description":"\n \n GHK-Cu, BPC-157, TB-500 og KPV, kolyofiliseret i et fast masseforhold på 50:10:10:10, 80 mg i alt. Mængder pr. komponent findes i materialespecifikationen nedenfor.\n \n \n En 15-residuers sekvens afledt af et protein i mavesaft, undersøgt i gnavermodeller med angiogenese, VEGFR2 og Akt-eNOS-signalvejen som den foreslåede mekanisme.\n \n \n Det komplette 43-aminosyre-peptid (masse omkring 4963 Da, CAS 77591-33-4), CoA-bekræftet. Det binder G-actin, monomeren i actin-cytoskelettet.\n \n \n Et kobber(II)-bindende tripeptid fra humant plasma. Fibroblastkulturstudier målte kollagensyntese på tværs af picomolære koncentrationer.\n \n \n Det C-terminale tripeptid af alfa-melanocytstimulerende hormon, undersøgt for NF-kB-signalering og for PepT1-optag i tarmmodeller.\n \n \n Intet studie, der tester disse fire peptider i ét forsøg, i nogen art, blev identificeret. Forholdet er et formuleringsvalg, ikke et fund.\n \n\n\n\n Kobberkompleks\n Kollagensyntese\n Actin-binding\n NF-kB-signalvej\n Gnavermodeller\n\n\n## Hvad er KLOW\n\nKLOW er en forskningsblanding af fire peptider i ét kolyofiliseret hætteglas: GHK-Cu, BPC-157, TB-500 og KPV i et fast masseforhold på 50:10:10:10, 80 mg i alt. Fordi de fire frysetørres sammen, før hætteglasset fyldes, er forholdet fastsat ved fremstillingen og kan ikke ændres ved rekonstitution.\n\nNavnet følger GLOW, tre-peptid-blandingen af GHK-Cu, BPC-157 og TB-500, med KPV, det C-terminale tripeptid af alfa-MSH, tilføjet som fjerde komponent. Det er hele forskellen mellem de to produkter: én komponent og 10 mg.\n\nVi leverer det som et kolyofiliseret pulver udelukkende til laboratorieforskning. I opløsning antager det en svag blå nuance, som stammer fra kobberionen i GHK-Cu.\n\n## Sådan virker det\n\nFire komponenter, fire separate litteraturer. Intet af resultaterne nedenfor blev genereret med peptiderne kombineret.\n\n**GHK-Cu** er et kobber(II)-bindende tripeptid identificeret i humant plasma. I dyrkede humane hudfibroblaster blev kollagensyntese målt på tværs af picomolære koncentrationer sammen med celletal (PMID 29986520 gennemgår de bredere genekspressionsdata).\n\n**BPC-157** er en 15-aminosyre-sekvens afledt af et mavesaftprotein. Dets gnaverlitteratur beskriver VEGFR2- og Akt-eNOS-signalering samt angiogenese som den foreslåede mekanisme (PMID 40789979, PMID 40005999).\n\n**TB-500** er fuldlængde thymosin beta-4, det primære G-actin-bindende peptid i de fleste celletyper. Det binder monomert actin; litteraturen om dermale og korneale modeller målte cytoskeletal organisering og cellemigration (PMID 10469335, PMID 23050815).\n\n**KPV** er de sidste tre rester af alfa-MSH. Publiceret arbejde måler NF-kB-signalvejsaktivitet og optag gennem den intestinale PepT1-transportør i colitismodeller (PMID 18061177, PMID 12750433).\n\nDet ærlige resumé er kort: fire separat undersøgte molekyler i ét hætteglas, intet kombinationsstudie bag forholdet, og et certifikat der rapporterer hver komponents målte indhold frem for ét blandet tal.\n\nTil rekonstitution er standardopløsningsmidlet i publicerede protokoller bakteriostatisk eller sterilt vand.\n\n\n\n\n\n## Dokumentation\n\n\n \n \n \n \n \n \n \n\n\n\n\n\n Curr Rev Musculoskelet Med, 2025; oversigt over gnaverlitteraturen og det kliniske evidensgab\n Pharmaceuticals, 2025; litteratur- og patentoversigt\n Ann N Y Acad Sci, 2012; oversigt over dermale modelstudier\n J Invest Dermatol, 1999; grundlæggende studie, reepitelisering og keratinocytmigration\n Int J Mol Sci, 2018; oversigt bygget på genekspressionsprofiler\n Gastroenterology, 2008; transportørvej samt musecolitismodeller\n J Pharmacol Exp Ther, 2003; signalvejssammenligning in vitro\n\n\n\nDette materiale sælges udelukkende til in vitro-forskning og laboratoriebrug. Ikke beregnet til human eller animalsk indtagelse, medicinsk, kosmetisk eller husholdningsmæssig anvendelse. Kun egnet til professionelle laboratoriemiljøer.\n","shortDescription":"KLOW er et kolyofiliseret hætteglas med GHK-Cu, BPC-157, TB-500 og KPV i et fast masseforhold på 50:10:10:10, 80 mg i alt. Hvert peptid har sin egen publicerede litteratur; intet studie har testet de fire sammen. Indhold pr. komponent på batch-CoA'en.","metaTitle":"Køb KLOW-blanding (GHK-Cu, BPC-157, TB-500, KPV) | EU","metaDescription":"KLOW: kolyofiliseret GHK-Cu, BPC-157, TB-500 og KPV i fast masseforhold 50:10:10:10. Janoshik-CoA pr. komponent, EU-forsendelse. Kun til in vitro-forskning."},{"id":"edd988a7-2d52-474d-84cb-c2ce4f7e9296","productId":"dca7c7e4-77af-4fff-9326-6eb7174d8650","locale":"fr","name":"KLOW","description":"\n \n GHK-Cu, BPC-157, TB-500 et KPV, co-lyophilisés selon un ratio massique fixe de 50:10:10:10, 80 mg au total. Les quantités par composant figurent dans la spécification du matériau ci-dessous.\n \n \n Une séquence de 15 résidus dérivée d'une protéine du suc gastrique, étudiée dans des modèles rongeurs avec l'angiogenèse, le récepteur VEGFR2 et la voie Akt-eNOS comme mécanisme proposé.\n \n \n Le peptide complet de 43 acides aminés (masse d'environ 4963 Da, CAS 77591-33-4), confirmé par CoA. Il lie la G-actine, le monomère du cytosquelette d'actine.\n \n \n Un tripeptide liant le cuivre(II), présent dans le plasma humain. Des études en culture de fibroblastes ont mesuré la synthèse de collagène sur une gamme de concentrations picomolaires.\n \n \n Le tripeptide C-terminal de l'hormone alpha-mélanotrope, étudié pour la signalisation NF-kB et l'entrée via PepT1 dans des modèles intestinaux.\n \n \n Aucune étude testant ces quatre peptides dans une même expérience, quelle que soit l'espèce, n'a été identifiée. Le ratio est un choix de formulation, pas un résultat.\n \n\n\n\n Complexe de cuivre\n Synthèse de collagène\n Liaison à l'actine\n Voie NF-kB\n Modèles rongeurs\n\n\n## Qu'est-ce que le KLOW\n\nKLOW est un mélange de recherche à quatre peptides dans un seul flacon co-lyophilisé : GHK-Cu, BPC-157, TB-500 et KPV selon un ratio massique fixe de 50:10:10:10, 80 mg au total. Comme les quatre sont lyophilisés ensemble avant le remplissage du flacon, le ratio est fixé à la fabrication et ne peut pas être modifié par la reconstitution.\n\nLe nom fait suite au GLOW, le mélange à trois peptides GHK-Cu, BPC-157 et TB-500, avec le KPV, le tripeptide C-terminal de l'alpha-MSH, ajouté comme quatrième composant. C'est toute la différence entre les deux produits : un composant et 10 mg.\n\nNous le fournissons sous forme de poudre co-lyophilisée, pour la recherche de laboratoire uniquement. En solution, il prend une légère teinte bleue, qui provient de l'ion cuivre du GHK-Cu.\n\n## Comment cela fonctionne\n\nQuatre composants, quatre littératures distinctes. Aucun des résultats ci-dessous n'a été établi avec les peptides combinés.\n\n**Le GHK-Cu** est un tripeptide liant le cuivre(II), identifié dans le plasma humain. Dans des fibroblastes cutanés humains en culture, la synthèse de collagène a été mesurée sur une gamme de concentrations picomolaires, ainsi que le nombre de cellules (le PMID 29986520 passe en revue les données d'expression génique plus larges).\n\n**Le BPC-157** est une séquence de 15 acides aminés dérivée d'une protéine du suc gastrique. Sa littérature chez le rongeur décrit la signalisation VEGFR2 et Akt-eNOS et l'angiogenèse comme mécanisme proposé (PMID 40789979, PMID 40005999).\n\n**Le TB-500** est la thymosine bêta-4 de pleine longueur, le principal peptide liant la G-actine dans la plupart des types cellulaires. Il lie l'actine monomérique ; la littérature sur les modèles dermiques et cornéens a mesuré l'organisation du cytosquelette et la migration cellulaire (PMID 10469335, PMID 23050815).\n\n**Le KPV** correspond aux trois derniers résidus de l'alpha-MSH. Les travaux publiés mesurent l'activité de la voie NF-kB et l'entrée via le transporteur intestinal PepT1 dans des modèles de colite (PMID 18061177, PMID 12750433).\n\nLe résumé honnête est court : quatre molécules étudiées séparément dans un seul flacon, aucune étude de combinaison derrière le ratio, et un certificat qui rapporte la teneur mesurée de chaque composant plutôt qu'un seul chiffre combiné.\n\nPour la reconstitution, le solvant standard des protocoles publiés est l'eau bactériostatique ou l'eau stérile.\n\n\n\n\n\n## Documentation\n\n\n \n \n \n \n \n \n \n\n\n\n\n\n Curr Rev Musculoskelet Med, 2025 ; revue de la littérature rongeur et de l'écart de preuves cliniques\n Pharmaceuticals, 2025 ; revue de la littérature et des brevets\n Ann N Y Acad Sci, 2012 ; revue des travaux en modèle dermique\n J Invest Dermatol, 1999 ; étude fondatrice, ré-épithélialisation et migration des kératinocytes\n Int J Mol Sci, 2018 ; revue basée sur des profils d'expression génique\n Gastroenterology, 2008 ; voie de transport et modèles de colite murine\n J Pharmacol Exp Ther, 2003 ; comparaison de voies in vitro\n\n\n\nCe matériau est vendu strictement pour la recherche in vitro et l'usage en laboratoire. Non destiné à la consommation humaine ou animale, ni à des applications médicales, cosmétiques ou domestiques. Convient uniquement aux environnements de laboratoire professionnels.\n","shortDescription":"Le KLOW est un flacon co-lyophilisé contenant du GHK-Cu, du BPC-157, du TB-500 et du KPV selon un ratio massique fixe de 50:10:10:10, 80 mg au total. Chaque peptide a sa propre littérature publiée ; aucune étude n'a testé les quatre ensemble. Teneur par composant sur le CoA du lot.","metaTitle":"Acheter KLOW (GHK-Cu, BPC-157, TB-500, KPV) | UE","metaDescription":"KLOW : GHK-Cu/BPC-157/TB-500/KPV co-lyophilisés, ratio massique fixe 50:10:10:10. CoA Janoshik par composant. Expédition UE. Recherche in vitro uniquement."},{"id":"ab560412-b66d-4092-9ac1-a42ce3fc98f9","productId":"dca7c7e4-77af-4fff-9326-6eb7174d8650","locale":"nl","name":"KLOW","description":"\n \n GHK-Cu, BPC-157, TB-500 en KPV, co-gelyofiliseerd in een vaste massaverhouding van 50:10:10:10, 80 mg totaal. Hoeveelheden per component staan in de materiaalspecificatie hieronder.\n \n \n Een sequentie van 15 residuen, afgeleid van een eiwit in maagsap, onderzocht in knaagdiermodellen met angiogenese, VEGFR2 en de Akt-eNOS-route als voorgesteld mechanisme.\n \n \n Het volledige peptide van 43 aminozuren (massa ongeveer 4963 Da, CAS 77591-33-4), via CoA bevestigd. Het bindt G-actine, de monomeer van het actinecytoskelet.\n \n \n Een koper(II)-bindend tripeptide uit humaan plasma. Fibroblastenkweekstudies maten collageensynthese over picomolaire concentraties.\n \n \n Het C-terminale tripeptide van het melanocytenstimulerend hormoon alfa, onderzocht op NF-kB-signalering en op PepT1-opname in darmmodellen.\n \n \n Er is geen studie gevonden die deze vier peptiden in één experiment testte, in enige diersoort. De verhouding is een formuleringskeuze, geen bevinding.\n \n\n\n\n Kopercomplex\n Collageensynthese\n Actinebinding\n NF-kB-route\n Knaagdiermodellen\n\n\n## Wat is KLOW\n\nKLOW is een onderzoeksblend van vier peptiden in één co-gelyofiliseerde flacon: GHK-Cu, BPC-157, TB-500 en KPV in een vaste massaverhouding van 50:10:10:10, 80 mg in totaal. Omdat de vier samen worden vriesgedroogd voordat de flacon wordt gevuld, ligt de verhouding vast bij de productie en kan deze niet door reconstitutie worden gewijzigd.\n\nDe naam volgt op GLOW, de driepeptidenblend van GHK-Cu, BPC-157 en TB-500, met KPV, het C-terminale tripeptide van alfa-MSH, toegevoegd als vierde component. Dat is het hele verschil tussen de twee producten: één component en 10 mg.\n\nWe leveren het als co-gelyofiliseerd poeder, uitsluitend voor laboratoriumonderzoek. In oplossing krijgt het een lichte blauwe tint, afkomstig van het koperion in GHK-Cu.\n\n## Hoe het werkt\n\nVier componenten, vier aparte literaturen. Geen van de onderstaande resultaten is gegenereerd met de peptiden gecombineerd.\n\n**GHK-Cu** is een koper(II)-bindend tripeptide dat is geïdentificeerd in humaan plasma. In gekweekte humane huidfibroblasten werd collageensynthese gemeten over picomolaire concentraties naast celaantal (PMID 29986520 geeft een overzicht van de bredere genexpressiegegevens).\n\n**BPC-157** is een sequentie van 15 aminozuren, afgeleid van een maagsap-eiwit. De knaagdierliteratuur erover beschrijft VEGFR2- en Akt-eNOS-signalering en angiogenese als het voorgestelde mechanisme (PMID 40789979, PMID 40005999).\n\n**TB-500** is thymosine bèta-4 in volledige lengte, het belangrijkste G-actine-bindende peptide in de meeste celtypen. Het bindt monomeer actine; de dermale en corneale modelliteratuur mat cytoskeletorganisatie en celmigratie (PMID 10469335, PMID 23050815).\n\n**KPV** is de laatste drie residuen van alfa-MSH. Gepubliceerd werk meet NF-kB-route-activiteit en opname via de intestinale PepT1-transporter in colitismodellen (PMID 18061177, PMID 12750433).\n\nDe eerlijke samenvatting is kort: vier apart onderzochte moleculen in één flacon, geen combinatiestudie achter de verhouding, en een certificaat dat het gemeten gehalte per component rapporteert in plaats van één gemengd getal.\n\nVoor reconstitutie is het standaardoplosmiddel in gepubliceerde protocollen bacteriostatisch of steriel water.\n\n\n\n\n\n## Documentatie\n\n\n \n \n \n \n \n \n \n\n\n\n\n\n Curr Rev Musculoskelet Med, 2025; overzicht van de knaagdierliteratuur en de klinische bewijskloof\n Pharmaceuticals, 2025; literatuur- en octrooioverzicht\n Ann N Y Acad Sci, 2012; overzicht van dermaal modelwerk\n J Invest Dermatol, 1999; grondleggende studie, re-epithelialisatie en keratinocytmigratie\n Int J Mol Sci, 2018; review gebouwd op genexpressieprofielen\n Gastroenterology, 2008; transporterroute plus muiscolitismodellen\n J Pharmacol Exp Ther, 2003; routevergelijking in vitro\n\n\n\nDit materiaal wordt uitsluitend verkocht voor in-vitro onderzoek en laboratoriumgebruik. Niet bedoeld voor menselijke of dierlijke consumptie, medische, cosmetische of huishoudelijke toepassingen. Alleen geschikt voor professionele laboratoriumomgevingen.\n","shortDescription":"KLOW is een co-gelyofiliseerde flacon met GHK-Cu, BPC-157, TB-500 en KPV in een vaste massaverhouding van 50:10:10:10, 80 mg totaal. Elk peptide heeft zijn eigen gepubliceerde literatuur; geen studie heeft de vier samen getest. Gehalte per component op het charge-CoA.","metaTitle":"KLOW-blend (GHK-Cu, BPC-157, TB-500, KPV) kopen | EU","metaDescription":"KLOW: co-gelyofiliseerd GHK-Cu/BPC-157/TB-500/KPV, vaste massaverhouding 50:10:10:10. Janoshik-CoA per component, EU-verzending. Alleen in-vitro onderzoek."},{"id":"4245597e-234e-4b9b-8f44-d0e7e5731e5c","productId":"dca7c7e4-77af-4fff-9326-6eb7174d8650","locale":"pl","name":"KLOW","description":"\n \n GHK-Cu, BPC-157, TB-500 i KPV, wspólnie liofilizowane w stałym stosunku masowym 50:10:10:10, łącznie 80 mg. Ilości poszczególnych składników znajdują się w specyfikacji materiału poniżej.\n \n \n 15-resztowa sekwencja pochodząca z białka soku żołądkowego, badana w modelach gryzoni, z angiogenezą, VEGFR2 i szlakiem Akt-eNOS jako proponowanym mechanizmem.\n \n \n Pełny 43-aminokwasowy peptyd (masa około 4963 Da, CAS 77591-33-4), potwierdzony CoA. Wiąże G-aktynę, monomer cytoszkieletu aktynowego.\n \n \n Tripeptyd wiążący miedź(II) z ludzkiego osocza. Badania na hodowlach fibroblastów zmierzyły syntezę kolagenu w zakresie stężeń pikomolarnych.\n \n \n C-końcowy tripeptyd hormonu alfa-melanotropowego, badany pod kątem sygnalizacji NF-kB oraz wychwytu przez PepT1 w modelach jelitowych.\n \n \n Nie zidentyfikowano żadnego badania testującego te cztery peptydy w jednym eksperymencie, u jakiegokolwiek gatunku. Stosunek to wybór formulacyjny, a nie wynik badania.\n \n\n\n\n Kompleks miedzi\n Synteza kolagenu\n Wiązanie aktyny\n Szlak NF-kB\n Modele gryzoni\n\n\n## Czym jest KLOW\n\nKLOW to badawcza mieszanka czterech peptydów w jednej wspólnie liofilizowanej fiolce: GHK-Cu, BPC-157, TB-500 i KPV w stałym stosunku masowym 50:10:10:10, łącznie 80 mg. Ponieważ cała czwórka jest suszona przez zamrażanie razem, zanim fiolka zostanie napełniona, stosunek ten jest ustalony na etapie produkcji i nie można go zmienić przez rekonstytucję.\n\nNazwa nawiązuje do GLOW, trzypeptydowej mieszanki GHK-Cu, BPC-157 i TB-500, z dodanym jako czwarty składnik KPV, C-końcowym tripeptydem alfa-MSH. To cała różnica między tymi dwoma produktami: jeden składnik i 10 mg.\n\nDostarczamy ją jako wspólnie liofilizowany proszek wyłącznie do badań laboratoryjnych. W roztworze przybiera lekki niebieski odcień, pochodzący od jonu miedzi w GHK-Cu.\n\n## Jak to działa\n\nCztery składniki, cztery osobne zbiory literatury. Żaden z poniższych wyników nie powstał przy peptydach połączonych razem.\n\n**GHK-Cu** to tripeptyd wiążący miedź(II), zidentyfikowany w ludzkim osoczu. W hodowlach ludzkich fibroblastów skóry zmierzono syntezę kolagenu w zakresie stężeń pikomolarnych wraz z liczbą komórek (PMID 29986520 omawia szersze dane dotyczące ekspresji genów).\n\n**BPC-157** to 15-aminokwasowa sekwencja pochodząca z białka soku żołądkowego. Jego literatura dotycząca gryzoni opisuje sygnalizację VEGFR2 i Akt-eNOS oraz angiogenezę jako proponowany mechanizm (PMID 40789979, PMID 40005999).\n\n**TB-500** to pełnej długości tymozyna beta-4, główny peptyd wiążący G-aktynę w większości typów komórek. Wiąże monomeryczną aktynę; literatura dotycząca modeli skóry i rogówki zmierzyła organizację cytoszkieletu i migrację komórek (PMID 10469335, PMID 23050815).\n\n**KPV** to ostatnie trzy reszty alfa-MSH. Opublikowane prace mierzą aktywność szlaku NF-kB oraz wychwyt przez jelitowy transporter PepT1 w modelach zapalenia jelita grubego (PMID 18061177, PMID 12750433).\n\nUczciwe podsumowanie jest krótkie: cztery osobno badane cząsteczki w jednej fiolce, żadnego badania kombinacji stojącego za tym stosunkiem, i certyfikat, który podaje zmierzoną zawartość każdego składnika, a nie jedną łączną liczbę.\n\nDo rekonstytucji standardowym rozpuszczalnikiem w opublikowanych protokołach jest woda bakteriostatyczna lub sterylna.\n\n\n\n\n\n## Dokumentacja\n\n\n \n \n \n \n \n \n \n\n\n\n\n\n Curr Rev Musculoskelet Med, 2025; przegląd literatury dotyczącej gryzoni i luki w dowodach klinicznych\n Pharmaceuticals, 2025; przegląd literatury i patentów\n Ann N Y Acad Sci, 2012; przegląd prac na modelach skóry\n J Invest Dermatol, 1999; fundamentalne badanie, reepitelizacja i migracja keratynocytów\n Int J Mol Sci, 2018; przegląd oparty na profilach ekspresji genów\n Gastroenterology, 2008; droga transportera oraz mysie modele zapalenia jelita grubego\n J Pharmacol Exp Ther, 2003; porównanie szlaków in vitro\n\n\n\nTen materiał jest sprzedawany ściśle do badań in vitro i użytku laboratoryjnego. Nie jest przeznaczony do spożycia przez ludzi ani zwierzęta, ani do zastosowań medycznych, kosmetycznych lub domowych. Nadaje się wyłącznie do profesjonalnych środowisk laboratoryjnych.\n","shortDescription":"KLOW to wspólnie liofilizowana fiolka zawierająca GHK-Cu, BPC-157, TB-500 i KPV w stałym stosunku masowym 50:10:10:10, łącznie 80 mg. Każdy peptyd ma własną opublikowaną literaturę; żadne badanie nie testowało tej czwórki razem. Zawartość poszczególnych składników na CoA partii.","metaTitle":"Kup mieszankę KLOW (GHK-Cu, BPC-157, TB-500, KPV) | UE","metaDescription":"KLOW: wspólnie liofilizowane GHK-Cu, BPC-157, TB-500 i KPV, stały stosunek masowy 50:10:10:10. CoA Janoshik dla składników, wysyłka UE. Tylko badania in vitro."},{"id":"2fdf37e3-e65c-4577-b472-551089d1bb7b","productId":"dca7c7e4-77af-4fff-9326-6eb7174d8650","locale":"pt","name":"KLOW","description":"\n \n GHK-Cu, BPC-157, TB-500 e KPV, co-liofilizados numa proporção mássica fixa de 50:10:10:10, 80 mg no total. As quantidades por componente constam da especificação do material abaixo.\n \n \n Uma sequência de 15 resíduos derivada de uma proteína do suco gástrico, estudada em modelos de roedores, com a angiogénese, o VEGFR2 e a via Akt-eNOS como mecanismo proposto.\n \n \n O péptido completo de 43 aminoácidos (massa de cerca de 4963 Da, CAS 77591-33-4), confirmado por CoA. Liga-se à G-actina, o monómero do citoesqueleto de actina.\n \n \n Um tripéptido ligante de cobre(II), do plasma humano. Estudos em cultura de fibroblastos mediram a síntese de colagénio em concentrações picomolares.\n \n \n O tripéptido C-terminal da hormona alfa-estimuladora dos melanócitos, estudado quanto à sinalização de NF-kB e à captação por PepT1 em modelos intestinais.\n \n \n Não foi identificado nenhum estudo que testasse estes quatro péptidos numa única experiência, em nenhuma espécie. A proporção é uma escolha de formulação, não uma conclusão.\n \n\n\n\n Complexo de cobre\n Síntese de colagénio\n Ligação à actina\n Via NF-kB\n Modelos de roedores\n\n\n## O que é o KLOW\n\nO KLOW é uma mistura de investigação de quatro péptidos, num único frasco co-liofilizado: GHK-Cu, BPC-157, TB-500 e KPV, numa proporção mássica fixa de 50:10:10:10, 80 mg no total. Como os quatro são liofilizados em conjunto antes de o frasco ser enchido, a proporção é fixada no fabrico e não pode ser alterada pela reconstituição.\n\nO nome segue o GLOW, a mistura de três péptidos de GHK-Cu, BPC-157 e TB-500, com o KPV, o tripéptido C-terminal da alfa-MSH, adicionado como quarto componente. Essa é toda a diferença entre os dois produtos: um componente e 10 mg.\n\nFornecemo-lo como pó co-liofilizado, exclusivamente para investigação laboratorial. Em solução, adquire uma leve tonalidade azul, proveniente do ião de cobre do GHK-Cu.\n\n## Como funciona\n\nQuatro componentes, quatro literaturas separadas. Nenhum dos resultados abaixo foi gerado com os péptidos combinados.\n\n**O GHK-Cu** é um tripéptido ligante de cobre(II), identificado no plasma humano. Em fibroblastos cutâneos humanos em cultura, a síntese de colagénio foi medida em concentrações picomolares, a par do número de células (o PMID 29986520 revê os dados mais alargados de expressão génica).\n\n**O BPC-157** é uma sequência de 15 aminoácidos derivada de uma proteína do suco gástrico. A sua literatura em roedores descreve a sinalização VEGFR2 e Akt-eNOS e a angiogénese como mecanismo proposto (PMID 40789979, PMID 40005999).\n\n**O TB-500** é a timosina beta-4 de comprimento total, o principal péptido ligante de G-actina na maioria dos tipos de células. Liga-se à actina monomérica; a literatura sobre modelos dérmicos e corneanos mediu a organização do citoesqueleto e a migração celular (PMID 10469335, PMID 23050815).\n\n**O KPV** são os últimos três resíduos da alfa-MSH. O trabalho publicado mede a atividade da via NF-kB e a captação através do transportador intestinal PepT1 em modelos de colite (PMID 18061177, PMID 12750433).\n\nO resumo honesto é curto: quatro moléculas estudadas separadamente num só frasco, nenhum estudo de combinação por trás da proporção, e um certificado que reporta o conteúdo medido de cada componente, em vez de um único número combinado.\n\nPara a reconstituição, o solvente padrão nos protocolos publicados é água bacteriostática ou estéril.\n\n\n\n\n\n## Documentação\n\n\n \n \n \n \n \n \n \n\n\n\n\n\n Curr Rev Musculoskelet Med, 2025; revisão da literatura em roedores e da lacuna de evidência clínica\n Pharmaceuticals, 2025; revisão da literatura e de patentes\n Ann N Y Acad Sci, 2012; revisão do trabalho em modelos dérmicos\n J Invest Dermatol, 1999; estudo fundador, reepitelização e migração de queratinócitos\n Int J Mol Sci, 2018; revisão assente em perfis de expressão génica\n Gastroenterology, 2008; via do transportador, mais modelos de colite em ratinhos\n J Pharmacol Exp Ther, 2003; comparação de vias in vitro\n\n\n\nEste material é vendido exclusivamente para investigação in vitro e uso laboratorial. Não se destina a consumo humano ou animal, nem a aplicações médicas, cosméticas ou domésticas. Adequado apenas para ambientes laboratoriais profissionais.\n","shortDescription":"O KLOW é um frasco co-liofilizado que contém GHK-Cu, BPC-157, TB-500 e KPV numa proporção mássica fixa de 50:10:10:10, 80 mg no total. Cada péptido tem a sua própria literatura publicada; nenhum estudo testou os quatro em conjunto. Conteúdo por componente no CoA do lote.","metaTitle":"Comprar Mistura KLOW (GHK-Cu, BPC-157, TB-500, KPV) | UE","metaDescription":"KLOW: GHK-Cu, BPC-157, TB-500 e KPV co-liofilizados na proporção mássica fixa 50:10:10:10. CoA Janoshik por componente, envio UE. Apenas investigação in vitro."},{"id":"8e839795-5ffe-4d84-a31e-ace3cd786b36","productId":"dca7c7e4-77af-4fff-9326-6eb7174d8650","locale":"sv","name":"KLOW","description":"\n \n GHK-Cu, BPC-157, TB-500 och KPV, samfrystorkade i ett fast massförhållande 50:10:10:10, totalt 80 mg. Mängder per komponent finns i materialspecifikationen nedan.\n \n \n En 15-rest-sekvens härledd från ett protein i magsaft, studerad i gnagarmodeller med angiogenes, VEGFR2 och Akt-eNOS-vägen som föreslagen mekanism.\n \n \n Den kompletta 43-aminosyra-peptiden (massa cirka 4963 Da, CAS 77591-33-4), CoA-bekräftad. Den binder G-aktin, monomeren i aktincytoskelettet.\n \n \n En koppar(II)-bindande tripeptid från human plasma. Fibroblastkulturstudier mätte kollagensyntes över pikomolära koncentrationer.\n \n \n Den C-terminala tripeptiden av alfa-melanocytstimulerande hormon, studerad för NF-kB-signalering och för PepT1-upptag i tarmmodeller.\n \n \n Ingen studie som testat dessa fyra peptider i ett och samma experiment, i någon art, identifierades. Förhållandet är ett formuleringsval, inte ett fynd.\n \n\n\n\n Kopparkomplex\n Kollagensyntes\n Aktinbindning\n NF-kB-vägen\n Gnagarmodeller\n\n\n## Vad är KLOW\n\nKLOW är en forskningsblandning av fyra peptider i en enda samfrystorkad flaska: GHK-Cu, BPC-157, TB-500 och KPV i ett fast massförhållande 50:10:10:10, totalt 80 mg. Eftersom de fyra frystorkas tillsammans innan flaskan fylls är förhållandet fastställt vid tillverkningen och kan inte ändras genom rekonstitution.\n\nNamnet följer GLOW, trepeptidblandningen av GHK-Cu, BPC-157 och TB-500, med KPV, den C-terminala tripeptiden av alfa-MSH, tillagd som en fjärde komponent. Det är hela skillnaden mellan de två produkterna: en komponent och 10 mg.\n\nVi levererar det som ett samfrystorkat pulver, endast för laboratorieforskning. I lösning får det en svag blå nyans, som kommer från kopparjonen i GHK-Cu.\n\n## Hur det fungerar\n\nFyra komponenter, fyra separata litteraturer. Inget av resultaten nedan genererades med peptiderna kombinerade.\n\n**GHK-Cu** är en koppar(II)-bindande tripeptid identifierad i human plasma. I odlade humana hudfibroblaster mättes kollagensyntes över pikomolära koncentrationer tillsammans med cellantal (PMID 29986520 granskar de bredare genuttrycksdata).\n\n**BPC-157** är en 15-aminosyra-sekvens härledd från ett magsaftprotein. Dess gnagarlitteratur beskriver VEGFR2- och Akt-eNOS-signalering och angiogenes som den föreslagna mekanismen (PMID 40789979, PMID 40005999).\n\n**TB-500** är fullängds tymosin beta-4, den huvudsakliga G-aktinbindande peptiden i de flesta celltyper. Den binder monomert aktin; den dermala och korneala modell-litteraturen mätte cytoskelettorganisation och cellmigration (PMID 10469335, PMID 23050815).\n\n**KPV** är de tre sista resterna av alfa-MSH. Publicerat arbete mäter NF-kB-vägsaktivitet och upptag via tarmens PepT1-transportör i kolitmodeller (PMID 18061177, PMID 12750433).\n\nDen ärliga sammanfattningen är kort: fyra separat studerade molekyler i en flaska, ingen kombinationsstudie bakom förhållandet, och ett certifikat som anger varje komponents uppmätta innehåll snarare än ett kombinerat tal.\n\nFör rekonstitution är standardlösningsmedlet i publicerade protokoll bakteriostatiskt eller sterilt vatten.\n\n\n\n\n\n## Dokumentation\n\n\n \n \n \n \n \n \n \n\n\n\n\n\n Curr Rev Musculoskelet Med, 2025; översikt av gnagarlitteraturen och den kliniska evidensluckan\n Pharmaceuticals, 2025; litteratur- och patentöversikt\n Ann N Y Acad Sci, 2012; översikt av dermalt modellarbete\n J Invest Dermatol, 1999; grundläggande studie, re-epitelisering och keratinocytmigration\n Int J Mol Sci, 2018; översikt byggd på genuttrycksprofiler\n Gastroenterology, 2008; transportörvägen plus musmodeller för kolit\n J Pharmacol Exp Ther, 2003; signalvägsjämförelse in vitro\n\n\n\nDetta material säljs uteslutande för in vitro-forskning och laboratoriebruk. Inte avsett för konsumtion av människor eller djur, medicinsk, kosmetisk eller hushållsanvändning. Endast lämpligt för professionella laboratoriemiljöer.\n","shortDescription":"KLOW är en samfrystorkad flaska med GHK-Cu, BPC-157, TB-500 och KPV i ett fast massförhållande 50:10:10:10, totalt 80 mg. Varje peptid har sin egen publicerade litteratur; ingen studie har testat de fyra tillsammans. Innehåll per komponent på batch-CoA.","metaTitle":"Köp KLOW-blandning (GHK-Cu, BPC-157, TB-500, KPV) | EU","metaDescription":"KLOW: GHK-Cu, BPC-157, TB-500 och KPV, samfrystorkade i fast massförhållande 50:10:10:10. Janoshik CoA per komponent, EU-frakt. Endast för in vitro-forskning."},{"id":"401698ad-b7c7-49b4-97bf-fc5c7101282e","productId":"dca7c7e4-77af-4fff-9326-6eb7174d8650","locale":"en","name":"KLOW","description":"\n \n GHK-Cu, BPC-157, TB-500 and KPV, co-lyophilized at a fixed 50:10:10:10 mass ratio, 80 mg total. Per-component amounts are on the material specification below.\n \n \n A 15-residue sequence derived from a protein in gastric juice, studied in rodent models with angiogenesis, VEGFR2 and the Akt-eNOS pathway as the proposed mechanism.\n \n \n The complete 43-amino-acid peptide (mass about 4963 Da, CAS 77591-33-4), CoA-confirmed. It binds G-actin, the monomer of the actin cytoskeleton.\n \n \n A copper(II)-binding tripeptide from human plasma. Fibroblast culture studies measured collagen synthesis across picomolar concentrations.\n \n \n The C-terminal tripeptide of alpha-melanocyte-stimulating hormone, studied for NF-kB signalling and for PepT1 uptake in intestinal models.\n \n \n No study testing these four peptides in one experiment, in any species, was identified. The ratio is a formulation choice, not a finding.\n \n\n\n\n Copper complex\n Collagen synthesis\n Actin binding\n NF-kB pathway\n Rodent models\n\n\n## What is KLOW\n\nKLOW is a research blend of four peptides in a single co-lyophilized vial: GHK-Cu, BPC-157, TB-500 and KPV at a fixed 50:10:10:10 mass ratio, 80 mg in total. Because the four are freeze-dried together before the vial is filled, the ratio is fixed at manufacture and cannot be changed by reconstitution.\n\nThe name follows GLOW, the three-peptide blend of GHK-Cu, BPC-157 and TB-500, with KPV, the C-terminal tripeptide of alpha-MSH, added as a fourth component. That is the whole difference between the two products: one component and 10 mg.\n\nWe supply it as a co-lyophilized powder for laboratory research only. In solution it takes on a faint blue tint, which comes from the copper ion in GHK-Cu.\n\n## How it works\n\nFour components, four separate literatures. None of the results below was generated with the peptides combined.\n\n**GHK-Cu** is a copper(II)-binding tripeptide identified in human plasma. In cultured human skin fibroblasts collagen synthesis was measured across picomolar concentrations alongside cell number (PMID 29986520 reviews the wider gene-expression data).\n\n**BPC-157** is a 15-amino-acid sequence derived from a gastric-juice protein. Its rodent literature describes VEGFR2 and Akt-eNOS signalling and angiogenesis as the proposed mechanism (PMID 40789979, PMID 40005999).\n\n**TB-500** is full-length thymosin beta-4, the principal G-actin-binding peptide in most cell types. It binds monomeric actin; the dermal and corneal model literature measured cytoskeletal organisation and cell migration (PMID 10469335, PMID 23050815).\n\n**KPV** is the last three residues of alpha-MSH. Published work measures NF-kB pathway activity and uptake through the intestinal PepT1 transporter in colitis models (PMID 18061177, PMID 12750433).\n\nThe honest summary is short: four separately studied molecules in one vial, no combination study behind the ratio, and a certificate that reports each component's measured content rather than one blended number.\n\nFor reconstitution, the standard solvent in published protocols is bacteriostatic or sterile water.\n\n\n\n\n\n## Documentation\n\n\n \n \n \n \n \n \n \n\n\n\n\n\n Curr Rev Musculoskelet Med, 2025; review of the rodent literature and the clinical evidence gap\n Pharmaceuticals, 2025; literature and patent review\n Ann N Y Acad Sci, 2012; review of dermal model work\n J Invest Dermatol, 1999; foundational study, re-epithelialisation and keratinocyte migration\n Int J Mol Sci, 2018; review built on gene-expression profiles\n Gastroenterology, 2008; transporter route plus mouse colitis models\n J Pharmacol Exp Ther, 2003; pathway comparison in vitro\n\n\n\nThis material is sold strictly for in-vitro research and laboratory use. Not intended for human or animal consumption, medical, cosmetic, or household applications. Suitable only for professional laboratory environments.\n","shortDescription":"KLOW is a co-lyophilized vial holding GHK-Cu, BPC-157, TB-500 and KPV at a fixed 50:10:10:10 mass ratio, 80 mg total. Each peptide has its own published literature; no study has tested the four together. Per-component content on the batch CoA.","metaTitle":"Buy KLOW Blend (GHK-Cu, BPC-157, TB-500, KPV) | EU","metaDescription":"KLOW: co-lyophilized GHK-Cu, BPC-157, TB-500 and KPV at a fixed 50:10:10:10 mass ratio. Per-component Janoshik CoA, EU dispatch. For in-vitro research only."},{"id":"fb613e08-461a-48db-8f08-ff18c1db5607","productId":"dca7c7e4-77af-4fff-9326-6eb7174d8650","locale":"fi","name":"KLOW","description":"\n \n GHK-Cu, BPC-157, TB-500 ja KPV, yhdessä lyofilisoituna kiinteässä 50:10:10:10-massasuhteessa, yhteensä 80 mg. Komponenttikohtaiset määrät ovat alla materiaalin spesifikaatiossa.\n \n \n 15 aminohappotähteen sekvenssi, joka on peräisin mahanesteen proteiinista, tutkittu jyrsijämalleissa ehdotetulla mekanismilla, joka koskee angiogeneesiä, VEGFR2:ta ja Akt-eNOS-reittiä.\n \n \n Täydellinen 43 aminohapon peptidi (massa noin 4963 Da, CAS 77591-33-4), CoA-vahvistettu. Se sitoutuu G-aktiiniin, aktiinitukirangan monomeeriin.\n \n \n Kupari(II):een sitoutuva tripeptidi ihmisen plasmasta. Fibroblastiviljelmätutkimukset mittasivat kollageenisynteesiä pikomolaarisissa pitoisuuksissa.\n \n \n Alfa-melanosyyttejä stimuloivan hormonin C-pään tripeptidi, tutkittu NF-kB-signaloinnin ja PepT1-oton osalta suolistomalleissa.\n \n \n Yhtään tutkimusta, jossa näitä neljää peptidiä olisi testattu yhdessä kokeessa millään lajilla, ei tunnistettu. Suhde on formulointivalinta, ei löydös.\n \n\n\n\n Kuparikompleksi\n Kollageenisynteesi\n Aktiiniin sitoutuminen\n NF-kB-reitti\n Jyrsijämallit\n\n\n## Mitä KLOW on\n\nKLOW on neljän peptidin tutkimussekoitus yhdessä lyofilisoidussa pullossa: GHK-Cu, BPC-157, TB-500 ja KPV kiinteässä 50:10:10:10-massasuhteessa, yhteensä 80 mg. Koska nämä neljä pakastekuivataan yhdessä ennen pullon täyttöä, suhde on kiinteä valmistuksesta lähtien eikä sitä voi muuttaa liuottamalla.\n\nNimi seuraa GLOW:ta, GHK-Cu:n, BPC-157:n ja TB-500:n kolmen peptidin sekoitusta, johon on lisätty KPV, alfa-MSH:n C-pään tripeptidi, neljäntenä komponenttina. Se on koko ero näiden kahden tuotteen välillä: yksi komponentti ja 10 mg.\n\nToimitamme sitä yhdessä lyofilisoituna jauheena yksinomaan laboratoriotutkimukseen. Liuoksessa siihen tulee hienoinen sininen sävy, joka johtuu GHK-Cu:n kupari-ionista.\n\n## Miten se toimii\n\nNeljä komponenttia, neljä erillistä kirjallisuutta. Yhtäkään alla olevista tuloksista ei ole tuotettu peptidien yhdistelmällä.\n\n**GHK-Cu** on kupari(II):een sitoutuva tripeptidi, joka tunnistettiin ihmisen plasmasta. Viljellyissä ihmisen ihon fibroblasteissa kollageenisynteesiä mitattiin pikomolaarisissa pitoisuuksissa solumäärän ohella (PMID 29986520 katsoo laajemman geeni-ilmentymisdatan).\n\n**BPC-157** on 15 aminohapon sekvenssi, joka on peräisin mahanesteen proteiinista. Sen jyrsijäkirjallisuus kuvaa ehdotettuna mekanismina VEGFR2- ja Akt-eNOS-signalointia sekä angiogeneesiä (PMID 40789979, PMID 40005999).\n\n**TB-500** on täyspitkä tymosiini beeta-4, useimpien solutyyppien pääasiallinen G-aktiiniin sitoutuva peptidi. Se sitoutuu monomeeriseen aktiiniin; iho- ja sarveiskalvomallikirjallisuus mittasi tukirangan järjestäytymistä ja solujen migraatiota (PMID 10469335, PMID 23050815).\n\n**KPV** on alfa-MSH:n kolme viimeistä aminohappotähdettä. Julkaistu tutkimustyö mittaa NF-kB-reitin aktiivisuutta ja ottoa suoliston PepT1-kuljettajan kautta koliittimalleissa (PMID 18061177, PMID 12750433).\n\nRehellinen yhteenveto on lyhyt: neljä erikseen tutkittua molekyyliä yhdessä pullossa, ei yhdistelmätutkimusta suhteen takana, ja todistus, joka raportoi kunkin komponentin mitatun pitoisuuden yhden sekoitetun luvun sijaan.\n\nLiuottamiseen julkaistuissa protokollissa käytetään vakioliuottimena bakteriostaattista tai steriiliä vettä.\n\n\n\n\n\n## Dokumentaatio\n\n\n \n \n \n \n \n \n \n\n\n\n\n\n Curr Rev Musculoskelet Med, 2025; jyrsijäkirjallisuuden ja kliinisen näyttöaukon katsaus\n Pharmaceuticals, 2025; kirjallisuus- ja patenttikatsaus\n Ann N Y Acad Sci, 2012; ihomallitutkimuksen katsaus\n J Invest Dermatol, 1999; perustava tutkimus, uudelleenepitelisaatio ja keratinosyyttien migraatio\n Int J Mol Sci, 2018; katsaus, joka perustuu geeni-ilmentymisprofiileihin\n Gastroenterology, 2008; kuljetusreitti sekä hiiren koliittimallit\n J Pharmacol Exp Ther, 2003; reittivertailu in vitro\n\n\n\nTätä materiaalia myydään yksinomaan in vitro -tutkimukseen ja laboratoriokäyttöön. Ei ole tarkoitettu ihmisten tai eläinten nautittavaksi eikä lääketieteelliseen, kosmeettiseen tai kotitalouskäyttöön. Soveltuu vain ammattimaiseen laboratorioympäristöön.\n","shortDescription":"KLOW on yhdessä lyofilisoitu pullo GHK-Cu:ta, BPC-157:ää, TB-500:aa ja KPV:tä kiinteässä massasuhteessa 50:10:10:10, yhteensä 80 mg. Kullakin peptidillä on oma julkaistu kirjallisuutensa; yksikään tutkimus ei ole testannut näitä neljää yhdessä. Komponenttikohtainen pitoisuus eräkohtaisessa CoA:ssa.","metaTitle":"Osta KLOW-sekoitus (GHK-Cu, BPC-157, TB-500, KPV) | EU","metaDescription":"KLOW: yhteislyofilisoitu GHK-Cu/BPC-157/TB-500/KPV, kiinteä massasuhde 50:10:10:10. Janoshik CoA komponenteittain, EU-toimitus. Vain in vitro -tutkimukseen."},{"id":"02d92ab3-f06f-4d40-9061-878e484035e0","productId":"dca7c7e4-77af-4fff-9326-6eb7174d8650","locale":"ru","name":"KLOW","description":"\n \n GHK-Cu, BPC-157, TB-500 и KPV, совместно лиофилизированные в фиксированном массовом соотношении 50:10:10:10, 80 мг в сумме. Содержание по каждому компоненту указано в спецификации материала ниже.\n \n \n Последовательность из 15 остатков, происходящая из белка желудочного сока, изучаемая на моделях грызунов с предполагаемым механизмом ангиогенеза, VEGFR2 и пути Akt-eNOS.\n \n \n Полная последовательность из 43 аминокислот (масса около 4963 Да, CAS 77591-33-4), подтверждённая по CoA. Связывает G-актин, мономер актинового цитоскелета.\n \n \n Трипептид, связывающий медь(II), из плазмы человека. Исследования на культуре фибробластов измеряли синтез коллагена в диапазоне пикомолярных концентраций.\n \n \n C-концевой трипептид альфа-меланоцитстимулирующего гормона, изучаемый в связи с сигнализацией NF-kB и поглощением через PepT1 на кишечных моделях.\n \n \n Исследования, тестирующего эти четыре пептида в одном эксперименте, ни на каком виде, не найдено. Соотношение - выбор состава, а не результат исследования.\n \n\n\n\n Комплекс меди\n Синтез коллагена\n Связывание актина\n Путь NF-kB\n Модели на грызунах\n\n\n## Что такое KLOW\n\nKLOW - исследовательская смесь из четырёх пептидов в едином совместно лиофилизированном флаконе: GHK-Cu, BPC-157, TB-500 и KPV в фиксированном массовом соотношении 50:10:10:10, 80 мг в сумме. Поскольку все четыре лиофилизируются вместе ещё до заполнения флакона, это соотношение фиксировано на этапе производства и не может быть изменено восстановлением.\n\nНазвание следует за GLOW - трёхкомпонентной смесью GHK-Cu, BPC-157 и TB-500, - к которой добавлен KPV, C-концевой трипептид alpha-MSH, в качестве четвёртого компонента. Это и есть вся разница между двумя продуктами: один компонент и 10 мг.\n\nМы поставляем его в виде совместно лиофилизированного порошка исключительно для лабораторных исследований. В растворе он приобретает слабый синий оттенок, который происходит от иона меди в GHK-Cu.\n\n## Как это работает\n\nЧетыре компонента, четыре отдельные литературы. Ни один из приведённых ниже результатов не был получен с использованием пептидов в комбинации.\n\n**GHK-Cu** - трипептид, связывающий медь(II), идентифицированный в плазме человека. В культивируемых фибробластах кожи человека синтез коллагена измеряли в диапазоне пикомолярных концентраций наряду с числом клеток (более широкие данные по экспрессии генов рассмотрены в обзоре PMID 29986520).\n\n**BPC-157** - последовательность из 15 аминокислот, происходящая из белка желудочного сока. Его литература на грызунах описывает сигнализацию через VEGFR2 и путь Akt-eNOS и ангиогенез как предполагаемый механизм (PMID 40789979, PMID 40005999).\n\n**TB-500** - полноразмерный тимозин бета-4, основной G-актин-связывающий пептид в большинстве типов клеток. Он связывает мономерный актин; литература по моделям кожи и роговицы измеряла организацию цитоскелета и миграцию клеток (PMID 10469335, PMID 23050815).\n\n**KPV** - последние три остатка alpha-MSH. Опубликованные работы измеряют активность пути NF-kB и поглощение через кишечный транспортёр PepT1 на моделях колита (PMID 18061177, PMID 12750433).\n\nЧестное резюме короткое: четыре отдельно изученные молекулы в одном флаконе, ни одного исследования комбинации, лежащего в основе соотношения, и сертификат, сообщающий измеренное содержание каждого компонента, а не единый показатель смеси.\n\nДля восстановления стандартным растворителем в опубликованных протоколах служит бактериостатическая или стерильная вода.\n\n\n\n\n\n## Документация\n\n\n \n \n \n \n \n \n \n\n\n\n\n\n Curr Rev Musculoskelet Med, 2025; обзор литературы на грызунах и пробела в клинических данных\n Pharmaceuticals, 2025; обзор литературы и патентов\n Ann N Y Acad Sci, 2012; обзор работ на кожных моделях\n J Invest Dermatol, 1999; основополагающее исследование, реэпителизация и миграция кератиноцитов\n Int J Mol Sci, 2018; обзор, построенный на профилях экспрессии генов\n Gastroenterology, 2008; путь через транспортёр плюс мышиные модели колита\n J Pharmacol Exp Ther, 2003; сравнение путей in vitro\n\n\n\nЭтот материал продаётся исключительно для исследований in vitro и лабораторного использования. Не предназначен для употребления человеком или животными, для медицинского, косметического или бытового применения. Подходит только для профессиональных лабораторных условий.\n","shortDescription":"KLOW - совместно лиофилизированный флакон с GHK-Cu, BPC-157, TB-500 и KPV в фиксированном массовом соотношении 50:10:10:10, 80 мг в сумме. У каждого пептида своя опубликованная литература; ни одно исследование не тестировало все четыре вместе. Содержание по каждому компоненту в CoA партии.","metaTitle":"Купить смесь KLOW (GHK-Cu, BPC-157, TB-500, KPV) | ЕС","metaDescription":"KLOW: GHK-Cu/BPC-157/TB-500/KPV, совместная лиофилизация, фикс. массовое соотношение 50:10:10:10. CoA Janoshik по компонентам. Отправка из ЕС. Только in vitro."},{"id":"9ebf16cd-82e3-40e7-b2db-cfd23ecd64ec","productId":"dca7c7e4-77af-4fff-9326-6eb7174d8650","locale":"cs","name":"KLOW","description":"\n \n GHK-Cu, BPC-157, TB-500 a KPV, společně lyofilizované v pevném hmotnostním poměru 50:10:10:10, celkem 80 mg. Množství jednotlivých složek jsou uvedena ve specifikaci materiálu níže.\n \n \n 15zbytková sekvence odvozená z proteinu v žaludeční šťávě, zkoumaná na hlodavčích modelech s angiogenezí, VEGFR2 a dráhou Akt-eNOS jako navrhovaným mechanismem.\n \n \n Kompletní 43aminokyselinový peptid (hmotnost přibližně 4963 Da, CAS 77591-33-4), potvrzený CoA. Váže G-aktin, monomer aktinového cytoskeletu.\n \n \n Tripeptid vázající měď(II) z lidské plazmy. Studie na kultuře fibroblastů měřily syntézu kolagenu napříč pikomolárními koncentracemi.\n \n \n C-terminální tripeptid alfa-melanocyty stimulujícího hormonu, zkoumaný z hlediska signalizace NF-kB a transportu PepT1 ve střevních modelech.\n \n \n Nebyla nalezena žádná studie testující tyto čtyři peptidy v jednom experimentu u jakéhokoli druhu. Poměr je formulační volba, ne zjištění.\n \n\n\n\n Komplex mědi\n Syntéza kolagenu\n Vazba na aktin\n Dráha NF-kB\n Modely hlodavců\n\n\n## Co je KLOW\n\nKLOW je výzkumná směs čtyř peptidů v jedné společně lyofilizované lahvičce: GHK-Cu, BPC-157, TB-500 a KPV v pevném hmotnostním poměru 50:10:10:10, celkem 80 mg. Protože jsou všechny čtyři lyofilizovány společně před naplněním lahvičky, poměr je pevně daný při výrobě a rekonstitucí jej nelze změnit.\n\nNázev navazuje na GLOW, směs tří peptidů GHK-Cu, BPC-157 a TB-500, ke které je přidán KPV, C-terminální tripeptid alfa-MSH, jako čtvrtá složka. To je celý rozdíl mezi oběma produkty: jedna složka a 10 mg.\n\nDodáváme jej jako společně lyofilizovaný prášek pouze pro laboratorní výzkum. V roztoku nabírá slabý modrý odstín, který pochází z iontu mědi v GHK-Cu.\n\n## Jak to funguje\n\nČtyři složky, čtyři samostatné literatury. Žádný z níže uvedených výsledků nebyl získán s peptidy kombinovanými.\n\n**GHK-Cu** je tripeptid vázající měď(II) identifikovaný v lidské plazmě. V kultivovaných lidských kožních fibroblastech byla syntéza kolagenu měřena napříč pikomolárními koncentracemi spolu s počtem buněk (PMID 29986520 shrnuje širší data o genové expresi).\n\n**BPC-157** je 15aminokyselinová sekvence odvozená z proteinu žaludeční šťávy. Jeho hlodavčí literatura popisuje jako navrhovaný mechanismus signalizaci VEGFR2 a Akt-eNOS a angiogenezi (PMID 40789979, PMID 40005999).\n\n**TB-500** je plnodélkový thymosin beta-4, hlavní peptid vázající G-aktin ve většině typů buněk. Váže monomerní aktin; literatura o kožních a rohovkových modelech měřila organizaci cytoskeletu a buněčnou migraci (PMID 10469335, PMID 23050815).\n\n**KPV** jsou poslední tři zbytky alfa-MSH. Publikovaná práce měří aktivitu dráhy NF-kB a příjem přes střevní transportér PepT1 v modelech kolitidy (PMID 18061177, PMID 12750433).\n\nPoctivé shrnutí je krátké: čtyři samostatně zkoumané molekuly v jedné lahvičce, žádná kombinační studie za tímto poměrem a certifikát, který uvádí naměřený obsah každé složky zvlášť, ne jedno kombinované číslo.\n\nPro rekonstituci je standardním rozpouštědlem v publikovaných protokolech bakteriostatická nebo sterilní voda.\n\n\n\n\n\n## Dokumentace\n\n\n \n \n \n \n \n \n \n\n\n\n\n\n Curr Rev Musculoskelet Med, 2025; přehled hlodavčí literatury a mezery v klinických důkazech\n Pharmaceuticals, 2025; přehled literatury a patentů\n Ann N Y Acad Sci, 2012; přehled práce na kožních modelech\n J Invest Dermatol, 1999; zakládající studie, reepitelizace a migrace keratinocytů\n Int J Mol Sci, 2018; přehled postavený na profilech genové exprese\n Gastroenterology, 2008; transportní cesta plus myší modely kolitidy\n J Pharmacol Exp Ther, 2003; srovnání drah in vitro\n\n\n\nTento materiál se prodává výhradně pro in vitro výzkum a laboratorní použití. Není určen k lidské ani zvířecí konzumaci, k medicínskému, kosmetickému ani domácímu použití. Vhodný pouze pro profesionální laboratorní prostředí.\n","shortDescription":"KLOW je společně lyofilizovaná lahvička obsahující GHK-Cu, BPC-157, TB-500 a KPV v pevném hmotnostním poměru 50:10:10:10, celkem 80 mg. Každý peptid má vlastní publikovanou literaturu; žádná studie netestovala tyto čtyři společně. Obsah jednotlivých složek je uveden na CoA šarže.","metaTitle":"Koupit směs KLOW (GHK-Cu, BPC-157, TB-500, KPV) | EU","metaDescription":"KLOW: lyofilizovaná směs GHK-Cu, BPC-157, TB-500 a KPV, pevný hmotnostní poměr 50:10:10:10. CoA Janoshik pro každou složku, EU doprava. Jen in vitro výzkum."},{"id":"819dd952-4dc3-4d4c-8623-f9ddec8ee6b6","productId":"dca7c7e4-77af-4fff-9326-6eb7174d8650","locale":"it","name":"KLOW","description":"\n \n GHK-Cu, BPC-157, TB-500 e KPV, co-liofilizzati in un rapporto fisso di massa 50:10:10:10, 80 mg totali. Le quantità per componente sono nelle specifiche del materiale qui sotto.\n \n \n Una sequenza di 15 residui derivata da una proteina del succo gastrico, studiata in modelli di roditore con angiogenesi, VEGFR2 e la via Akt-eNOS come meccanismo proposto.\n \n \n Il peptide completo di 43 amminoacidi (massa circa 4963 Da, CAS 77591-33-4), confermato dal CoA. Lega la G-actina, il monomero del citoscheletro actinico.\n \n \n Un tripeptide legante il rame(II) dal plasma umano. Gli studi su coltura di fibroblasti hanno misurato la sintesi di collagene a concentrazioni picomolari.\n \n \n Il tripeptide C-terminale dell'ormone stimolante i melanociti alfa, studiato per la segnalazione NF-kB e per la captazione via PepT1 in modelli intestinali.\n \n \n Non è stato individuato alcuno studio che testasse questi quattro peptidi in un unico esperimento, in nessuna specie. Il rapporto è una scelta di formulazione, non un riscontro.\n \n\n\n\n Complesso del rame\n Sintesi di collagene\n Legame all'actina\n Via NF-kB\n Modelli nel roditore\n\n\n## Cos'è KLOW\n\nKLOW è una miscela di ricerca a quattro peptidi in un unico flaconcino co-liofilizzato: GHK-Cu, BPC-157, TB-500 e KPV in un rapporto fisso di massa 50:10:10:10, 80 mg in totale. Poiché i quattro vengono essiccati per congelamento insieme prima che il flaconcino venga riempito, il rapporto è fissato alla produzione e non può essere modificato dalla ricostituzione.\n\nIl nome segue GLOW, la miscela a tre peptidi di GHK-Cu, BPC-157 e TB-500, con il KPV, il tripeptide C-terminale dell'alfa-MSH, aggiunto come quarto componente. Questa è l'intera differenza tra i due prodotti: un componente e 10 mg.\n\nLo forniamo come polvere co-liofilizzata solo per la ricerca di laboratorio. In soluzione assume una tenue tonalità blu, che deriva dallo ione rame nel GHK-Cu.\n\n## Come agisce\n\nQuattro componenti, quattro letterature separate. Nessuno dei risultati sotto riportati è stato generato con i peptidi combinati.\n\n**Il GHK-Cu** è un tripeptide legante il rame(II) identificato nel plasma umano. In fibroblasti cutanei umani in coltura, la sintesi di collagene è stata misurata a concentrazioni picomolari insieme al numero di cellule (il PMID 29986520 passa in rassegna i dati più ampi di espressione genica).\n\n**Il BPC-157** è una sequenza di 15 amminoacidi derivata da una proteina del succo gastrico. La sua letteratura nel roditore descrive la segnalazione VEGFR2 e Akt-eNOS e l'angiogenesi come meccanismo proposto (PMID 40789979, PMID 40005999).\n\n**Il TB-500** è la timosina beta-4 a lunghezza intera, il principale peptide legante la G-actina nella maggior parte dei tipi cellulari. Lega l'actina monomerica; la letteratura sui modelli dermici e corneali ha misurato l'organizzazione del citoscheletro e la migrazione cellulare (PMID 10469335, PMID 23050815).\n\n**Il KPV** è costituito dagli ultimi tre residui dell'alfa-MSH. Il lavoro pubblicato misura l'attività della via NF-kB e la captazione attraverso il trasportatore intestinale PepT1 in modelli di colite (PMID 18061177, PMID 12750433).\n\nIl riepilogo onesto è breve: quattro molecole studiate separatamente in un unico flaconcino, nessuno studio di combinazione dietro il rapporto, e un certificato che riporta il contenuto misurato di ciascun componente anziché un unico valore combinato.\n\nPer la ricostituzione, il solvente standard nei protocolli pubblicati è acqua batteriostatica o sterile.\n\n\n\n\n\n## Documentazione\n\n\n \n \n \n \n \n \n \n\n\n\n\n\n Curr Rev Musculoskelet Med, 2025; rassegna della letteratura nel roditore e del divario di evidenza clinica\n Pharmaceuticals, 2025; rassegna della letteratura e dei brevetti\n Ann N Y Acad Sci, 2012; rassegna del lavoro sui modelli dermici\n J Invest Dermatol, 1999; studio fondativo, ri-epitelizzazione e migrazione dei cheratinociti\n Int J Mol Sci, 2018; rassegna costruita su profili di espressione genica\n Gastroenterology, 2008; via del trasportatore più modelli di colite nel topo\n J Pharmacol Exp Ther, 2003; confronto di vie in vitro\n\n\n\nQuesto materiale è venduto esclusivamente per uso di ricerca in vitro e di laboratorio. Non destinato al consumo umano o animale, né ad applicazioni mediche, cosmetiche o domestiche. Adatto solo ad ambienti di laboratorio professionali.\n","shortDescription":"KLOW è un flaconcino co-liofilizzato contenente GHK-Cu, BPC-157, TB-500 e KPV in un rapporto fisso di massa 50:10:10:10, 80 mg totali. Ogni peptide ha una propria letteratura pubblicata; nessuno studio ha testato i quattro insieme. Contenuto per componente sul CoA di lotto.","metaTitle":"Acquista la Miscela KLOW (GHK-Cu, BPC-157, TB-500, KPV) | UE","metaDescription":"KLOW: GHK-Cu, BPC-157, TB-500 e KPV co-liofilizzati, rapporto in massa 50:10:10:10. CoA Janoshik per componente, spedizione UE. Solo per ricerca in vitro."}],"variants":[{"id":"99e35881-527d-4194-b1c5-d2ba0fd38651","productId":"dca7c7e4-77af-4fff-9326-6eb7174d8650","sku":"PD-KLOW80-80MG","dosage":"80mg","price":115.99,"compareAtPrice":129.99,"stock":34,"maxQuantityPerOrder":0,"weight":null,"isDefault":true,"isVisible":true}],"labReports":[{"id":"c89b272f-ceb9-4360-9ba4-9fc56d1dce14","productId":"dca7c7e4-77af-4fff-9326-6eb7174d8650","batchNumber":"White lids (80mg)","testDate":"2026-07-30T00:00:00.000Z","labName":"Janoshik","reportUrl":"https://peptidesdirect.io/media/pep-shop/documents/klow-80mg-coa-janoshik-215332.jpg","verificationUrl":"https://verify.janoshik.com/tests/215332_EWHV99C7W6BJ","publicCode":null,"purity":null,"content":"GHK-Cu 45.99 mg · BPC-157 10.84 mg · TB-500 10.95 mg · KPV 10.74 mg","source":"manufacturer","testedIdentity":true,"testedPurity":false,"testedContent":true,"testedMicrobial":false,"testedEndotoxin":false,"testedHeavyMetals":false,"endotoxinEuMg":null,"heavyMetalsPass":null,"microbialPass":null,"createdAt":"2026-03-02T17:52:38.288Z"}],"tags":["healing"],"images":[{"id":"8e54e8bd-fb9b-42f4-a4b2-dcf755702728","productId":"dca7c7e4-77af-4fff-9326-6eb7174d8650","url":"https://peptidesdirect.io/media/pep-shop/images/klow__80mg__obsidian-2026-08.jpg","alt":"KLOW 80mg vial","sortOrder":0,"variantId":"99e35881-527d-4194-b1c5-d2ba0fd38651","createdAt":"2026-08-18T12:46:56.347Z"}],"faqs":[{"locale":"en","question":"What is KLOW?","answer":"KLOW is a four-peptide research blend in a single 80 mg vial: GHK-Cu, BPC-157, TB-500 and KPV, co-lyophilized at a fixed 50:10:10:10 mass ratio. GHK-Cu is a copper-binding tripeptide, BPC-157 a 15-residue gastric peptide, TB-500 the full-length 43-amino-acid actin-binding protein thymosin beta-4, and KPV the C-terminal tripeptide of alpha-MSH. Each carries its own separate published literature; no study testing the four together was identified. Per-component amounts are on the material specification. Supplied for laboratory research only.","sortOrder":0},{"locale":"en","question":"How should I store KLOW?","answer":"Lyophilized KLOW is commonly kept at -20°C for longer storage or at 2-8°C for short-term storage. After reconstitution, the usual laboratory convention is refrigeration at 2-8°C and use within about 30 days; this is standard peptide-handling practice, not a stability result measured for this product. Protection from light and moisture is part of the usual handling convention.","sortOrder":1},{"locale":"en","question":"What purity is your KLOW blend?","answer":"Every batch of KLOW ships with a certificate of analysis from Janoshik Analytical, an independent third-party laboratory. The current report covers identity and content per component; purity was not assayed on that batch, so no purity figure is stated for it. We do not run a lab ourselves: the manufacturer commissions the test, and we pass the report on unchanged, with an online verification link on the product page.","sortOrder":2},{"locale":"en","question":"How do I reconstitute KLOW?","answer":"Add bacteriostatic water slowly along the inside wall of the vial. Gently swirl until dissolved - do not shake. Use the recommended volume as indicated on the product label.","sortOrder":3},{"locale":"en","question":"How do KLOW's four peptides, GHK-Cu, BPC-157, TB-500 and KPV, relate to each other according to the published research?","answer":"They do not share one pathway: each of the four has its own separately studied mechanism, and no published study has combined them in one experiment. BPC-157 is described as acting through the VEGFR2 receptor and the Akt-eNOS pathway, with angiogenesis and histological tissue endpoints as readouts in rat models (PMID 40789979). TB-500, full-length thymosin beta-4, is a G-actin-sequestering peptide whose foundational mechanistic work measured endothelial and myocardial cell migration (PMID 15565145), with separate model work in mouse, rat and pig (PMID 25015963, PMID 10469335, PMID 27199757). GHK-Cu was studied for collagen synthesis (PMID 3169264) and for bFGF and VEGF output in cultured human skin fibroblasts (PMID 15655171). KPV was studied for NF-kB and MAP-kinase signalling and for colonic inflammation markers in mouse colitis models (PMID 18061177).","sortOrder":4},{"locale":"en","question":"Is BPC-157, TB-500, GHK-Cu or KPV approved by the FDA, EMA, or any regulator?","answer":"None of the four peptides in KLOW, BPC-157, TB-500, GHK-Cu or KPV, holds a marketing authorisation from the EMA or the FDA for any medical use; all four remain unapproved research compounds. GHK-Cu is a partial exception in that the peptide-research literature describes it as an ingredient in cosmetic products in some markets (PMID 26236730), which is a cosmetic-ingredient status rather than a drug approval. Thymosin beta-4, studied as RGN-259 and RGN-352, has been through registered human trials: the ARISE-1 to ARISE-3 dry-eye programme (ClinicalTrials.gov NCT02597803, NCT02974907, NCT03937882) and a cardiac trial (NCT05984134). Neither route produced an approved drug. BPC-157 has one actively enrolling Phase 2 trial (NCT07437547) with no results reported yet.","sortOrder":10},{"locale":"en","question":"Is the TB-500 in KLOW the full-length peptide or the short fragment some vendors sell, and does that matter?","answer":"The TB-500 in KLOW is the full-length, 43-amino-acid thymosin beta-4 (molecular mass about 4963 Da, CAS 77591-33-4), the same molecule used in the cardiac, dermal and corneal studies cited for this product, not the short Ac-LKKTETQ fragment that some vendors label \"TB-500.\" Our own third-party CoA confirms this identity for the batch we ship, which matters because the cited research (for example the dry-eye phase 2 trial, PMID 25826322, and the mouse infarction study, PMID 25015963) was conducted on the full-length peptide, and those results would not apply to the shorter fragment. Buyers should check a vendor's CoA before assuming any \"TB-500\" product is the studied molecule, since the two are structurally different peptides sold under the same market name.","sortOrder":11},{"locale":"en","question":"What does our own third-party CoA show for KLOW, and how can a specific batch be verified?","answer":"The most recent Janoshik report on batch White lids, tested 30 July 2026, states measured content per vial: GHK-Cu 45.99 mg, BPC-157 10.84 mg, TB-500 10.95 mg, KPV 10.74 mg. This report covers identity and amount only: the laboratory explicitly notes that peptide purity was not included in this analysis, so no purity figure is stated for this batch. Janoshik is an independent third-party laboratory, but this particular test was commissioned by the manufacturer, not by us, and we publish the report unchanged. Anyone can verify the result at verify.janoshik.com using the batch's test number 215332. If a vial shows a different batch code, that batch's own report is the one that applies.","sortOrder":13},{"locale":"en","question":"How is KLOW different from GLOW, since GLOW is sold too?","answer":"GLOW is the three-peptide version: GHK-Cu, BPC-157 and TB-500, 70 mg total per vial. KLOW holds those three components plus KPV, 80 mg total. KPV is the C-terminal tripeptide of alpha-MSH, studied for NF-kB and MAP-kinase signalling in mouse colitis models (PMID 18061177). Both are co-lyophilized at a fixed ratio rather than mixed at the bench, and the literature for each shared component is the same for both products, because it comes from the same single-peptide studies. Neither has been studied as an assembled blend; the comparison sits at the level of the individual peptides.","sortOrder":14},{"locale":"en","question":"Why is KLOW sold as a fixed 50/10/10/10 mg blend instead of four separate vials?","answer":"The four peptides are co-lyophilized, combined into one powder before the vial is freeze-dried, so a single reconstitution always delivers them in the same 50:10:10:10 mg ratio and there is no way to separate them again afterwards. This is how most suppliers produce combination blends like KLOW and GLOW: it reflects research-market practice rather than a published combination study. Anyone who wants a different ratio, or wants to vary one component independently, can buy GHK-Cu, BPC-157, TB-500 and KPV separately, since we sell each on its own. We are not aware of any published study that tested whether the fixed 50:10:10:10 ratio itself has any significance beyond the four single-peptide literatures it draws on.","sortOrder":15},{"locale":"en","question":"Does the copper in KLOW's GHK-Cu component affect how the vial looks or behaves once reconstituted?","answer":"Reconstituted KLOW takes on a faint blue tint from the copper in the GHK-Cu complex, which is expected and not a sign of contamination or degradation. This differs visibly from single-peptide vials like plain BPC-157 or TB-500, which reconstitute clear. We have not found any published stability study that specifically measured whether the copper complex changes the degradation rate of BPC-157, TB-500 or KPV once combined in the same vial, so the general refrigerated-use window on the label is a standard peptide-stability convention, not a result from a study of this exact four-peptide mixture.","sortOrder":16},{"locale":"en","question":"How long does reconstituted KLOW stay stable, and how should the vial be stored before and after mixing?","answer":"The unopened lyophilized KLOW vial is commonly kept frozen at -20°C and out of light until reconstitution. Add bacteriostatic water slowly down the inside wall of the vial and swirl gently, never shake. Once mixed, the usual convention is to store the solution refrigerated at 2 to 8°C, out of light, and avoid repeated freeze-thaw cycles or extended time at room temperature. As a practical guideline, consistent with the window used for other reconstituted lyophilized peptides in our catalogue, the usual convention is use within about 2 to 4 weeks. No stability study for this specific four-peptide combination was identified, so this is a conservative handling guideline based on general peptide-storage practice rather than a validated figure for KLOW itself.","sortOrder":18},{"locale":"en","question":"Is the KLOW blend actually better value than buying GHK-Cu, BPC-157, TB-500 and KPV separately?","answer":"KLOW is one 80 mg vial at a fixed 50:10:10:10 mass ratio, and its price sits slightly below the sum of the four single-peptide listings at current catalogue prices. The trade-off is that fixed ratio and a single reconstitution step, instead of four separate vials that stay independent. Researchers who want all four components in that exact ratio have the simpler route here; anyone who wants a different ratio, more of one component, or only one or two of the four is better served by the individual listings. Current prices are on each product page.","sortOrder":19},{"locale":"en","question":"How much bacteriostatic water should be used to reconstitute KLOW's 80 mg vial, and what concentration (mg per mL) does that produce?","answer":"There is no single required water volume for KLOW: the amount added only sets the concentration in milligrams per millilitre. As dilution arithmetic, adding 4 mL of bacteriostatic water to the 80 mg vial yields a 20 mg/mL stock solution; 2 mL yields 40 mg/mL; 8 mL yields 10 mg/mL. Our reconstitution calculator at /research/reconstitution-calculator works this out for any chosen volume. What never changes is the 50:10:10:10 mg ratio between GHK-Cu, BPC-157, TB-500 and KPV, fixed when the four peptides are co-lyophilized: more or less water only concentrates or dilutes the mixture, it never shifts the balance between the components.","sortOrder":20},{"locale":"en","question":"Does unrefrigerated shipping affect the quality of this product?","answer":"This product ships unrefrigerated as a lyophilised (freeze-dried) powder in a sealed vial. Solid formulations are frequently required to maintain protein stability during storage and transport (PMID 25565441); temperature and moisture influence degradation in the solid state (PMID 10229638). Solid human insulin was studied for six months at 25°C and 40°C (PMID 39725225), solid semaglutide retained its native structure up to 60°C (PMID 42086873), and a freeze-dried secretin formulation showed a 20 to 27 percent assay decrease at eight weeks (PMID 25636302). Our parcels travel 1 to 2 working days within Germany and 3 to 10 across the EU, longer outside the EU. After delivery, store the sealed vial refrigerated or frozen, and refrigerate after reconstitution. The cited studies describe other solid peptide formulations; they do not measure this specific product, so we state the transit facts and the storage rules rather than a guarantee.","sortOrder":25},{"locale":"en","question":"Is reconstituted GHK-Cu expected to look bright blue, and does uneven powder, clumping, or gritty residue mean it's fake or degraded?","answer":"The blue is chemistry, not branding: the bound copper(II) ion gives GHK-Cu solutions their blue-to-blue-green tint, which our pages document as the expected optical signature, and GLOW and KLOW take on the same tint from their GHK-Cu share, while a copper-free blend like WOLVERINE does not. Shade intensity varies with concentration and lighting, so 'less vivid than someone's photo' is not a potency reading. On the dry cake: pharmaceutical freeze-drying literature documents that shrinkage, cracking, uneven texture and patchy appearance occur even in fully in-spec GMP products (PMID 28341598), because cake cosmetics depend on the drying run, not on content; no published appearance specification for copper-peptide lyophilizates was identified. So an uneven or partially clumped cake is not, by itself, evidence of a fake or degraded vial. The judgments that DO matter are the after-reconstitution ones our troubleshooting pages define: gentle technique first (room temperature, water down the glass wall, swirl, rest), a slight haze occurs with many peptides and often clears within 5 to 20 minutes, while persistent turbidity, solid flecks that never dissolve, or anything resembling growth is a reject, and visible particulate matter is a formal rejection category in injectable-product practice generally. Identity and content live in the batch CoA, not in the cake's looks; and a vial that fails the dissolve test is a case for our replacement process, not for squinting.","sortOrder":29}],"ratingAvg":0,"ratingCount":0,"productReviews":[]}